CG Oncology, Inc. Common stock (CGON) - Stock Analysis

Last updated: Sep 20, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

A November 16 Phase 3 update reported a statistically significant 68% reduction in recurrence risk. Shares gained about 27% over 21 trading days through November 17, although the post-result pullback signals volatility.

Loading chart data...

Idea window: 11/18/2026 – 11/25/2026Sector: Healthcare

AI Analyst Overview

Last Price
$79.47
Market Cap
$7.10B
1D Return
-2.97%
YTD Return
+91.40%

Loading chart data...

Valuation Metrics

P/E
-28.7
P/B
7.1
P/S
1151.2
EV/EBITDA
-30.4
Div Yield
—

Fundamental Analysis

5.0

Key Financial Insights: • Strong Liquidity • Heavy Cash Burn • Persistent Losses CGON has ample liquidity and minimal debt, but severe losses, cash burn, dilution, and an extreme valuation make it a high-risk investment pending meaningful revenue growth.

HighRisk
Liquidity

Price Behavior

5.0

Key Price Behavior Insights: • Mild downtrend • $72 support • $75.90 resistance Support Level: $72.00 Resistance Level: $75.60–$75.90 CGON is mildly bearish over the last month, with support at $72.00 and resistance near $75.90; a breakout above resistance would improve momentum, while a break below support raises downside risk.

CGON
TechnicalOutlook

Sentiment & News

5.0

Key News Insights: • Conference visibility • Institutional buying • Investor interest CG Oncology's conference appearances and Jupiter Topco's $1.63M share purchase increase investor visibility and signal institutional interest.

CGOncology
InvestorInterest
AI

AI Summary

5.0
Neutral

CGON is no longer a funding-risk biotech but a richly valued, catalyst-driven execution trade: its ~$1B runway supports development through delays, yet the $6B+ valuation leaves little room for anything short of compelling PIVOT-006 data, regulatory clearance, and rapid commercial adoption of cretostimogene. Investors should treat positive Phase III results as the key upside trigger while recognizing that weak data, CMC setbacks, or slow launch uptake could drive a sharp valuation reset.

PIVOT006
ValuationRisk
FDA
AI summary updated 61 days ago

Description

CG Oncology Inc. is a clinical-stage biopharmaceutical company developing a potential bladder-sparing therapeutic for patients with bladder cancer. Its lead candidate, cretostimogene, is in clinical development for high-risk non-muscle invasive bladder cancer in patients who do not respond to Bacillus Calmette-GuĂŠrin therapy.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Nov 18Nov 25CGONCG Oncology, Inc. Common stock
A November 16 Phase 3 update reported a statistically significant 68% reduction in recurrence risk. Shares gained about 27% over 21 trading days through November 17, although the post-result pullback signals volatility.
Active+2.4%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.